Serdemetan enhances bone regeneration by coordinated regulation of osteoblast and osteoclast activity through the p53 pathway

Serdemetan, an MDM2 inhibitor traditionally known for anticancer activity, demonstrates dual pro-osteogenic and anti-osteoclastic effects via p53 activation, showing bone regenerative efficacy comparable to alendronate in preclinical models. Overall design: Comparative gene expression profiling analysis of RNA-seq data for Serdemetan treatment or control cells Please note that paired-end R1/R2 reads for the hBMSC samples were analyzed separately as single-end dataset, resulting in 4 data columns in the hBMSC_read_count.csv.